Welcome to our dedicated page for Sunshine Biopharma news (Ticker: SBFM), a resource for investors and traders seeking the latest updates and insights on Sunshine Biopharma stock.
Sunshine Biopharma Inc. reports developments as a pharmaceutical company with commercial generic prescription drugs in Canada and proprietary drug-development programs in oncology and antivirals. News commonly covers product launches through its Nora Pharma subsidiary, including generic medicines such as Domperidone, Doxycycline and Pravastatin, as well as Health Canada commercialization approvals and expansion of therapeutic categories.
The company’s updates also address financial results, portfolio growth and research programs including K1.1 mRNA, an mRNA-lipid nanoparticle candidate targeting liver cancer, and a PLpro protease inhibitor for SARS-related coronavirus infections. Corporate and treasury actions may appear alongside operating updates when they affect Sunshine Biopharma’s capital strategy or public-company profile.
Sunshine Biopharma (NASDAQ:SBFM) has announced the launch of two new generic prescription drugs through its Canadian subsidiary, Nora Pharma Inc. The first product is Varenicline, a generic version of Champix®, used for smoking cessation. It's available in 0.5 mg and 1 mg tablets, plus a starter kit. The second is Betahistine, a generic version of Serc®, for treating vertigo, available in 8 mg, 16 mg, and 24 mg scored tablets.
These additions expand Nora Pharma's portfolio to 63 products, strengthening its position in the $9.7 billion Canadian generic drug market. Sunshine Biopharma's CEO, Dr. Steve Slilaty, expressed anticipation for more product launches in the near future, while Nora Pharma's president, Mr. Malek Chamoun, highlighted expectations for continued rapid growth.
Sunshine Biopharma (NASDAQ:SBFM) has announced the publication of significant coronavirus research results in the Journal of Medicinal Chemistry. The study, conducted in collaboration with the University of Arizona, reveals a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with submicromolar potency and efficacy in animal models.
Key findings include:
- XR8-23 showed significant drug accumulation in mouse lungs and favorable pharmacokinetic properties
- The compound exhibited broad-spectrum antiviral activity against multiple SARS-CoV-2 variants
- It demonstrated in vivo activity in a mouse-adapted SARS-CoV-2 infection model at 10 mg/kg by repeated IV injections
This research marks an important milestone in Sunshine Biopharma's efforts to develop an effective treatment for SARS-CoV-2 infection, particularly for high-risk and immunocompromised patients.
Sunshine Biopharma (NASDAQ:SBFM) has expanded its generic drug portfolio in Canada, launching nine new prescription drugs in 2024. This brings the company's total marketed drugs to 61. The new additions include Abiraterone, Clobetasol, Daptomycin, Dasatinib, Ertapenem, Hanzema®, Progesterone, Rivaroxaban, and Zoledronic Acid, addressing various health areas such as oncology, anti-inflammatory, antibacterial, dermatology, endocrinology, cardiovascular, and osteoporosis.
These drugs are currently sold under distribution agreements, differing from Nora Pharma's usual cross-licensing arrangements. The expansion aims to strengthen Sunshine Biopharma's presence in the $9.7 billion Canadian generic drug market and improve access to pharmacies. The company anticipates additional product launches in the near future.
Sunshine Biopharma (NASDAQ:SBFM) reported strong financial results for Q2 2024, with significant revenue growth. Key highlights include:
- Q2 revenues of $9,303,067, up 67% year-over-year
- YTD revenues of $16,844,113, up 61% year-over-year
- Q2 net loss decreased by 45% to $(494,300)
- YTD net loss decreased by 32% to $(1,778,101)
- Shareholders' Equity grew 11% to $23,489,865
The company attributes this growth to new product launches and expanded marketing efforts by its Canadian subsidiary, Nora Pharma Inc. CEO Dr. Steve Slilaty expressed confidence in achieving profitability through innovative strategies and operational optimization.
Sunshine Biopharma (NASDAQ:SBFM) has announced a 1-for-20 reverse stock split, effective August 8, 2024. This strategic move aims to regain compliance with Nasdaq's minimum bid price requirement for continued listing. The pharmaceutical company, which focuses on life-saving medicines in oncology and antivirals, is taking this step to maintain its position on the Nasdaq exchange. This decision highlights the company's commitment to meeting regulatory standards and potentially improving its market position.
Sunshine Biopharma (NASDAQ:SBFM) announced its 2024 first-quarter results, showing a 54% increase in gross revenues to $7.54 million, up from $4.89 million in the same period of 2023. The surge is attributed to new product launches and expanded marketing by its Canadian subsidiary, Nora Pharma. Despite the revenue growth, the company reported a net loss of $1.28 million, an improvement over the $1.70 million loss in the first quarter of 2023. The company also completed a public offering in February 2024, raising $10 million in gross proceeds, with $8.52 million net proceeds. Sunshine Biopharma is focused on achieving profitability.
Summary not available.
Summary not available.
Summary not available.
Summary not available.